Cardiol Therapeutics (CT9) Price & Analysis

0 Followers

CT9 Stock Chart & Stats

€1.84

-€0.04(-3.63%)

At close: Jul 24 4:00 PM EDT

€1.84

-€0.04(-3.63%)

Day’s Range― - ―

52-Week Range€0.73 - €1.95

Previous CloseN/A

Volume0.00

Average Volume (3M)1.48K

Market Cap

€194.32M

Enterprise Value€145.28

Total Cash (Recent Filing)€26.08M

Total Debt (Recent Filing)€107.00K

Price to Earnings (P/E)―

Beta0.65

Next Earnings

Nov 12, 2026

EPS Estimate

-0.05

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.34

Shares Outstanding116,822,670

10 Day Avg. Volume750

30 Day Avg. Volume1,478

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)6.37

Price to Sales (P/S)0.00

P/FCF Ratio-4.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€8.79

Price Target Upside377.79% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.28

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low debt limits financing pressure and preserves balance-sheet flexibility while Cardiol advances its pipeline. This provides greater capacity to raise capital or support development without the added burden of substantial interest expense or near-term debt repayment.

Clinical Pipeline FocusCardiol is focused on developing anti-inflammatory and anti-fibrotic treatments for important cardiovascular diseases. Progress across recurrent pericarditis and heart-failure programs could create multiple future commercialization opportunities if clinical and regulatory milestones are achieved.

Funding FlexibilityThe proposed shelf registration would give Cardiol a broader and more flexible framework for accessing capital as clinical programs advance. That financing capacity can support continued research and trials, although actual proceeds and financing terms remain dependent on future offerings.

Bears Say

Pre-revenue BusinessCardiol has no meaningful commercial revenue to fund operations while its drug candidates remain unapproved. The company therefore depends on clinical progress and eventual commercialization, leaving financial performance highly exposed to development outcomes over the coming quarters.

Persistent Cash BurnSustained negative operating and free cash flow means Cardiol must continue funding research and operations without internally generated cash. This creates ongoing external financing needs and can pressure capital allocation as clinical development expenses continue.

Declining Capital BaseThe reduction in equity and assets indicates that ongoing losses have consumed a meaningful portion of the company’s capital base. Even with minimal debt, continued erosion could reduce financial resilience and increase reliance on future equity or other external financing.

Cardiol Therapeutics News

Cardiol Therapeutics achieves enrollment target for Phase III MAVERIC trial

Cardiol Therapeutics (CRDL) announced enrollment progress and plans to expand MAVERIC, the Company’s pivotal Phase III randomized, double-blind,...

1d ago

CRDL

Cardiol Therapeutics receives over $7M in proceeds from warrant exercise

Cardiol Therapeutics (CRDL) is pleased to announce it has received proceeds of over $7M from the exercise of...

8d ago

CRDL

Cardiol Therapeutics files $150M preliminary base shelf prospectus

Cardiol Therapeutics (CRDL) announced that it has filed a preliminary short form base shelf prospectus with the securities...

14d ago

CRDL

Cardiol Therapeutics initiated with a Buy at B. Riley

B. Riley initiated coverage of Cardiol Therapeutics (CRDL) with a Buy rating and $11 price target The firm...

29d ago

CRDL

Cardiol Therapeutics Expands Phase III MAVERIC Trial After Early Enrollment Milestone

Cardiol Therapeutics ( ($TSE:CRDL) ) has shared an update. On September 23, 2026, Cardiol Therapeutics reported that it...

1d ago

CRDL

Cardiol Therapeutics Bolsters Cash Runway with $7 Million Warrant Exercise Ahead of Phase III Data

Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an update. Cardiol Therapeutics has raised over USD $7 million through...

8d ago

CRDL

Cardiol Therapeutics Bolsters Governance With Updated Code of Conduct Filing

Cardiol Therapeutics ( ($TSE:CRDL) ) just unveiled an announcement. On September 14, 2026, Cardiol Therapeutics filed a Form...

9d ago

CRDL

Cardiol Therapeutics Details Long-Term Manufacturing and Development Agreements in September SEC Filing

Cardiol Therapeutics ( ($TSE:CRDL) ) has provided an announcement. On September 10, 2026, Cardiol Therapeutics Inc. filed a...

13d ago

CRDL

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus After OSC Review

Cardiol Therapeutics ( ($TSE:CRDL) ) has issued an announcement. Cardiol Therapeutics said on Sept. 10, 2026, that it...

14d ago

CRDL

Cardiol Therapeutics to Showcase Cardiac Drug Pipeline at H.C. Wainwright Conference

The latest announcement is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics said it will take part...

15d ago

CRDL

Cardiol Therapeutics price target raised to $10 from $8 at Canaccord

Canaccord raised the firm’s price target on Cardiol Therapeutics (CRDL) to $10 from $8 and keeps a Buy...

1M ago

CRDL

Cardiol Therapeutics Reports Second-Quarter 2026 Interim Results

Cardiol Therapeutics ( ($TSE:CRDL) ) just unveiled an update. Cardiol Therapeutics filed a Form 6-K on August 12,...

1M ago

CRDL

Edward Nash Reaffirms Buy on Cardiol with Unchanged $8 Price Target, Citing Strong MAVERIC Trial Design and Attractive CardiolRx Commercial Prospects

Edward Nash, an analyst from Canaccord Genuity, reiterated the Buy rating on Cardiol Therapeutics. The associated price target...

1M ago

CRDL

Cardiol Therapeutics to Present Heart Disease Pipeline at Canaccord Genuity Growth Conference

The latest update is out from Cardiol Therapeutics ( ($TSE:CRDL) ). Cardiol Therapeutics announced on August 5, 2026,...

2M ago

CRDL

CT9 FAQ

What was Cardiol Therapeutics’s price range in the past 12 months?

Cardiol Therapeutics lowest stock price was €0.73 and its highest was €1.95 in the past 12 months.

What is Cardiol Therapeutics’s market cap?

Cardiol Therapeutics’s market cap is €194.32M.

When is Cardiol Therapeutics’s upcoming earnings report date?

Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 49 days.

How were Cardiol Therapeutics’s earnings last quarter?

Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -€0.031 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.029.

Is Cardiol Therapeutics overvalued?

According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cardiol Therapeutics pay dividends?

Cardiol Therapeutics does not currently pay dividends.

What is Cardiol Therapeutics’s EPS estimate?

Cardiol Therapeutics’s EPS estimate is -0.05.

How many shares outstanding does Cardiol Therapeutics have?

Cardiol Therapeutics has 116,822,670 shares outstanding.

What happened to Cardiol Therapeutics’s price movement after its last earnings report?

Cardiol Therapeutics reported an EPS of -€0.031 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went up 1.634%.

Which hedge fund is a major shareholder of Cardiol Therapeutics?

Currently, no hedge funds are holding shares in DE:CT9

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Cardiol Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

41.62%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Cardiol Therapeutics

Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.

Cardiol Therapeutics (CT9) Earnings & Revenues

Historic Earnings Reports

CT9 Stock 12 Month Forecast

Average Price Target

€8.79

▲(377.79% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","-1":"-€1","1.75":"€1.75","4.5":"€4.5","7.25":"€7.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.670431650000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€9.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.791301500000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€8.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.91217135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€7.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.75,4.5,7.25,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.313110126923077,2.9262202538461537,3.539330380769231,4.152440507692308,4.765550634615385,5.378660761538462,5.991770888461539,6.604881015384616,7.217991142307693,7.83110126923077,8.444211396153847,9.057321523076924,{"y":9.670431650000001,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.2454847307692307,2.7909694615384617,3.3364541923076922,3.8819389230769232,4.427423653846154,4.972908384615385,5.518393115384616,6.063877846153847,6.609362576923078,7.154847307692309,7.70033203846154,8.24581676923077,{"y":8.791301500000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.7,2.1778593346153845,2.6557186692307693,3.1335780038461536,3.6114373384615384,4.089296673076923,4.567156007692308,5.045015342307693,5.522874676923077,6.000734011538462,6.478593346153847,6.956452680769232,7.434312015384616,{"y":7.91217135,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.886,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.842,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.868,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.751,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.751,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.811,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.094,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.12,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.861,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >